open access

Vol 13, No 1 (2018)
Review Papers
Get Citation

Combination therapy in hypertension: a fixed-dose combination of perindopril, amlodipine and indapamide

Beata Wożakowska-Kapłon
DOI: 10.5603/FC.2018.0006
·
Folia Cardiologica 2018;13(1):35-38.

open access

Vol 13, No 1 (2018)
Review Papers

Abstract

Hypertension is one of the epidemiologically most important causes of death in the world. At the same time, its incidence
is constantly increasing. Effective control of blood pressure plays a key role in reducing cardiovascular risk and
overall mortality. Unfortunately, the majority of Polish patients do not reach the target blood pressure. Improvements in
this area can be obtained by using fixed-dose combination drugs. This article, on the basis of the presented clinical case,
discusses the benefits of combined antihypertensive therapy, in particular the fixed-dose combination of perindopril
with amlodipine and indapamide.

Abstract

Hypertension is one of the epidemiologically most important causes of death in the world. At the same time, its incidence
is constantly increasing. Effective control of blood pressure plays a key role in reducing cardiovascular risk and
overall mortality. Unfortunately, the majority of Polish patients do not reach the target blood pressure. Improvements in
this area can be obtained by using fixed-dose combination drugs. This article, on the basis of the presented clinical case,
discusses the benefits of combined antihypertensive therapy, in particular the fixed-dose combination of perindopril
with amlodipine and indapamide.

Get Citation

Keywords

arterial hypertension, therapy, complex drugs, amlodipine, perindopril, indapamide

About this article
Title

Combination therapy in hypertension: a fixed-dose combination of perindopril, amlodipine and indapamide

Journal

Folia Cardiologica

Issue

Vol 13, No 1 (2018)

Pages

35-38

DOI

10.5603/FC.2018.0006

Bibliographic record

Folia Cardiologica 2018;13(1):35-38.

Keywords

arterial hypertension
therapy
complex drugs
amlodipine
perindopril
indapamide

Authors

Beata Wożakowska-Kapłon

References (14)
  1. Yusuf S, Hawken S, Ôunpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. The Lancet. 2004; 364(9438): 937–952.
  2. Zdrojewski T, Bandosz P, Szpakowski P. Ocena wybranych proble- mów dotyczących rozpowszechnienia i terapii nadciśnienia tętniczego w Polsce na podstawie badania NATPOL-PLUS. W: Postępy w nefrologii i nadciśnieniu tętniczym. Vol II. Medycyna Praktyczna, Kraków. ; 2002: 11–15.
  3. Drygas W, Niklas AA, Piwońska A, et al. Multi-centre National Population Health Examination Survey (WOBASZ II study): assumptions, methods, and implementation. Kardiol Pol. 2016; 74(7): 681–690.
  4. Tykarski A, Narkiewicz K, Gaciong Z, et al. Zasady postępowania w nadciśnieniu tętniczym - 2015 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciś Tętn Prakt. 2015; 1: 1–70.
  5. Tykarski A, Widecka K, Narkiewicz K, et al. Leki złożone w terapii nadciśnienia tętniczego w Polsce. Stanowisko Ekspertów Polskiego Towarzystwa Nadciśnienia Tętniczego oraz Sekcji Farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa Kardiologicznego. Kardiol Pol. 2017; 75(12): 1357–1367.
  6. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2017 [Epub ahead of print].
  7. Dahlöf B, Sever PS, Poulter NR, et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial . Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. 2005(366): 895–906.
  8. Williams B, O'Rourke M. Anglo-Scandinavian Cardiac Outcomes Trial. The Conduit Artery Functional Endpoint (CAFE) study in ASCOT. J Hum Hypertens. 2001; 15 Suppl 1: S69–S73.
  9. Beckett N, Peters R, Fletcher A, et al. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine. 2008; 358(18): 1887–1898.
  10. Patel A, MacMahon S, Chalmers J, et al. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007; 370(9590): 829–840.
  11. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. The Lancet. 2001; 358(9287): 1033–1041.
  12. Páll D, Szántó I, Szabó Z. Triple combination therapy in hypertension: the antihypertensive efficacy of treatment with perindopril, amlodipine, and indapamide SR. Clin Drug Investig. 2014; 34(10): 701–708.
  13. Tóth K. PIANIST Investigators. Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients). Am J Cardiovasc Drugs. 2014; 14(2): 137–145.
  14. Ábrahám G, Dézsi CA. The Antihypertensive Efficacy of the Triple Fixed Combination of Perindopril, Indapamide, and Amlodipine: The Results of the PETRA Study. Adv Ther. 2017; 34(7): 1753–1763.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl